Request Demo

Last update 10 Feb 2025

Colecalciferol

Last update 10 Feb 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-vitamin D3, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol, (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol

+ [29]

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [4]

Active Indication

Vitamin D DeficiencyFamilial Hypophosphatemic RicketsHypoparathyroidism+ [2]

Inactive Indication

AsthmaChronic heart failureCrohn Disease+ [10]

Originator Organization

Abiogen Pharma SpA

Active Organization

Italfarmaco SpA

Zensun (Shanghai) Sci & Tech Co., Ltd.

George Mason University

+ [5]

Inactive Organization

Hayat Pharmaceutical Industries Co. Ltd.

University of AarhusAlvogen Korea Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

CA (01 Jan 1985),

Familial Hypophosphatemic RicketsHypoparathyroidism

Regulation-

Structure/Sequence

Molecular FormulaC27H44O

InChIKeyQYSXJUFSXHHAJI-YRZJJWOYSA-N

CAS Registry67-97-0

2,496

Clinical Trials associated with Colecalciferol

NCT06791044

/ Not yet recruitingNot ApplicableIIT

25(OH)-vitamin D and Its Association with Bone Density, Body Composition, Strength, Walking Speed, Physical Performance and Pain in Hospitalized Individuals with Neurological Disorders

The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters.
The NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed.
The study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers.
The findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.

Start Date01 Jun 2025

Sponsor / Collaborator-

CTRI/2024/10/075550

/ Not yet recruitingPhase 3IIT

A clinical study to evaluate the efficacy of lakshadi guggulu and Haridra (lakadong turmeric) in improving Vitamin D deficiency in asthikshaya condition of NE region - NA

Start Date03 Mar 2025

Sponsor / Collaborator-

ChiCTR2500096134

/ SuspendedPhase 4IIT

The study on the effect of vitamin D in preventing immune-related adverse reactions in patients with diabetes mellitus

Start Date01 Feb 2025

Sponsor / Collaborator

Changxing County People's Hospital

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

27,999

Literatures (Medical) associated with Colecalciferol

01 Dec 2025·IMMUNOLOGIC RESEARCH

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Article

Author: Naseri, Bahar ; Baradaran, Behzad ; Ghahramanipour, Zahra ; Sohrabi, Sepideh ; Karimzadeh, Hadi ; Mardi, Amirhossein ; Baghbani, Elham ; Masoumi, Javad

Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method. To differentiate monocytes from DCs, we utilized GM-CSF and IL-4 cytokines. Tolerogenic DCs were generated using vitamin D3 and dexamethasone. We added LPS and AVP to the culture medium on day 6 after incubation of DCs at 37 °C. Finally, we assessed the surface molecules by flow cytometry and used real-time PCR to evaluate the expression of genes related to the inhibitory immune checkpoints. Based on the obtained data, AVP increased the expression of CD11c (P ≤ 0.0001), HLA-DR (P ≤ 0.01), and CD86 (P ≤ 0.01) in AVP-mDCs. Also, the expression of all the immune checkpoint genes including CTLA-4 (P ≤ 0.001), BTLA (P ≤ 0.001), PDL-1 (P ≤ 0.05), B7H7 (P ≤ 0.001), LAG3 (P ≤ 0.01), and VISTA (P ≤ 0.001) in AVP-mDCs was increased in comparison to the control group. Vasopressin caused the generation of mature and tolerogenic DCs. Our data may help to consider AVP-mDCs to take part in autoimmune disease therapy, transplanted tissue rejection impedance, and allergies.

01 Jun 2025·Toxicology reports

Vitamin D supplementation: Biochemical and inflammatory effects in non-pathological Wistar rats

Article

Author: Erminda Schreiner, Gênifer ; Smolski Dos Santos, Laura ; Gonçalves, Itamar Luís ; Manfredini, Vanusa ; Casanova Petry, Charline ; Gomes Schmitt, Elizandra ; Muller de Moura Sarmento, Silvia ; Tamborena Malheiros, Rafael ; Klock, Clóvis

Vitamin D₃ (VD₃) is shown to be a biochemical and physiological modulator of the body. Debates about route of administration, prescribed dosage and serum levels have arisen, and thus the interaction of VD₃ with the body in overdose. Using an experimental model of Wistar rats of both sexes, rats were subdivided into 5 groups, which represents a control group, and 4 groups with VD₃ treatments (2.500, 7.000, 14.000 and 21.000 IU/kg/week) for one month. Thereafter biochemical, hormonal, inflammatory and histological analyses were performed. Regarding the biochemical findings, there was an increase in the levels of the AST in comparison of the control group with the treatments with higher doses (14.000 IU and 21.000 IU). Furthermore, changes in the inflammatory cytokine profile were identified at doses of 14,000 IU and 21,000 IU, with an increase in inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α) and a decrease in the anti-inflammatory IL-10. Histological evaluation of the liver tissue also revealed changes at the highest doses. Finally, in the evaluation of a murine physiological model, it showed that the supplementation of VD₃ in overdoses there was an inflammatory exacerbation in the body, suggesting that the VD₃ supplementation should be administered with caution, and takes into account physiological factors of the individual.

01 Apr 2025·TISSUE & CELL

Vitamin D3 mitigates aspirin-induced gastric injury by modulating gastrokines, E-cadherin, and inhibiting NLRP3 and NF-κB/MMP-9 signaling pathway

Article

Author: Talaat, Aliaa ; El-Sayed, Sherein F ; Samy, Walaa ; Wahid, Reham M ; Seada, Sara G ; Mahmoud, Samar Mortada

BACKGROUND:

The prevalence of gastric ulcers has grown significantly in the modern era affecting 10 % of global population. Aspirin downregulates gastrokines 1(GKN1) expression in gastric mucosa and GKN1 down-regulation results in gastric cancer. Vitamin D3 (Vit.D3) has anti-inflammatory and antioxidant effects.

AIM:

Study the gastroprotective impact of Vit.D3 following aspirin-induced gastric injury in relation to gastrokines and investigate the possible underlying mechanisms.

MATERIALS AND METHODS:

24 rats were divided into 4 groups: control, Vit.D3 supplemented normal, aspirin-induced gastric injury, and Vit.D3 supplemented gastric injury groups. Some oxidative stress markers with gene expression of GKN1&2, mucin 5AC (Muc5ac) and NLR family pyrin domain containing 3 (NLRP3) in the gastric tissue were done. Histopathological and immunohistochemical study of E-Cadherin, nuclear factor kappa beta (NFκB), and metalloproteinase-9 (MMP-9) in the stomach mucosa were identified.

RESULTS:

Vit.D3 supplementation significantly upregulated E-Cadherin, GSH, GKN1 and Muc5ac in the gastric tissue. Also, it improved the morphology, histology of gastric tissue, by alleviating oxidative stress and NFκB, MMP-9 and down regulation of inflammasome (NLRP3).

CONCLUSION:

Vitamin D3 has a potential protective effect against aspirin -induced gastric injury via upregulating gastrokine1 and E-cadherin and down regulation of NFKB/MMP-9 signaling pathway and NLRP3 inflammasome.

142

News (Medical) associated with Colecalciferol

06 Feb 2025

·www.drugs.com

Vitamin D in Early Pregnancy Could Boost Baby's Health

THURSDAY, Feb 6, 2024 -- Getting enough vitamin D, the "sunshine vitamin," during early pregnancy could be important for infant health, new research suggests. Researchers at Penn State found that infants born to women deficient in the nutrient were more likely to be delivered prematurely. Those newborns were also more likely to be smaller compared to babies delivered by women who'd gotten enough of the vitamin in their first trimester. “This study provides evidence that early pregnancy -- and even pre-conception -- nutrition is vitally important,” lead study author Celeste Beck said. She was a doctoral student at Penn State's University Park campus when the study was conducted, and is now an associate research scientist at Heluna Health. “We can't just assume that everybody is deficient, but proper nutrition is something that needs to be on your radar if you may become pregnant," senior study author Alison Gernand , associate professor of nutritional sciences at Penn State, added. “This study provides evidence that vitamin D appears to be an important part of a pregnant woman’s nutritional health," Gernand said. The research appears in the February issue of American Journal of Clinical Nutrition . Vitamin D is considered essential to health, and the body generates it naturally via the absorption of sunlight by the skin. However, many people no longer get enough vitamin D in their daily lives. In fact, prior research has found that “more than 25% of women who are pregnant or lactating have lower than recommended levels of vitamin D,” noted Gernand. “A lot of the development early in pregnancy requires vitamin D, so we conducted this study to better understand how early-pregnancy vitamin D status is related to pregnancy outcomes," she explained in a Penn State news release. Vitamin D insufficiency is defined as blood levels of the nutrient that are below 50 nanomoles per liter (nmol/L) of blood. In the new study, the researchers looked at first trimester vitamin D levels of 351 pregnant U.S. women who'd enrolled in a major federal study between 2010 and 2013. At first, there appeared to be no differences in pregnancy outcomes for women who were either above or below the 50 nmol/L blood level for vitamin D. But concerning differences did arise when researchers looked at a wider range of vitamin D concentrations. As Gerland and Beck reported, women with blood levels lower than 40 nmol/L during their first trimester had rates of preterm birth that were four times that of women who had vitamin D levels of 80 nmol/L or above. What's more, there was a trend to smaller babies (based on fetal length) among women as vitamin D levels during the first trimester decreased. The researchers stressed that these results are preliminary: There were few premature births in the study group overall, so a larger study may be needed to confirm the findings. Vitamin D levels during the second trimester appeared to have no relation to pregnancy outcomes. That could be because vitamin D levels tended to improve among the women later in pregnancy, although more study is needed to understand the finding, the researchers said. The take-home message from the study: Women may need to boost their vitamin D levels early in pregnancy. “Individual women may or may not need supplements depending on their diet and lifestyle," Gerland said. "But healthy nutrition is critical for promoting the healthy development of a fetus. This research indicates that vitamin D levels -- along with iron, folate and other essential nutrients in pregnancy -- should be monitored and understood by obstetricians and women early on to promote healthy birth outcomes.” The study was funded by the U.S. National Institutes of Health, the University of Utah and the Penn State Department of Nutritional Sciences. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

30 Dec 2024

·www.prnewswire.com

2025 Wellness Survey: Sauna Tops Recovery Practices People Want to Try; Building Muscle Remains Top New Year's Fitness Goal in Annual Life Time Poll

When asked about GLP-1 drugs, more than 60% believe the medications can improve overall health CHANHASSEN, Minn., Dec. 30, 2024 /PRNewswire/ -- As 2025 approaches, Life Time (NYSE: LTH) has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. Notable findings include: Continue Reading As 2025 approaches, Life Time has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. When asked which post-workout recovery practices people are interested in trying – or increasing – in 2025: 69.1% of respondents named using a sauna, while 50% said assisted stretching, and 42.4% chose ice baths or cryotherapy. When asked about GLP-1 drugs, 60.8% believe these medications have the potential to improve overall health. A high percentage (74.7%) plan to prioritize their health in 2025, compared to 62.4% of respondents who focused more on their health in 2024. A nearly 20% increase! 99.3% of respondents confirmed they feel happier after completing a workout, reinforcing the mental health benefits of getting your sweat on. For the third consecutive year, building muscle is the top health goal heading into the New Year, followed by eating better, moving more in general and weight loss. Strength training places as the top preferred workout routine, just ahead of cardio-focused workouts. "People of all ages are realizing the benefits of strength training and recovery by making it a priority in their routine," said Danny King, Director of Recovery and Performance at Life Time. "At Life Time, we're continuing to expand the size of our strength training spaces and recovery zones on our exercise floors, prioritizing equipment that fits a variety of body types and doubling down on our digital content. Our free Life Time Digital app is making it easier than ever for people to get started with strength training routines through classes and coaching at their fingertips." Survey respondents addressed 17 questions about their health, exercise habits, workouts and other topics: When it comes to nutrition, over 65% of respondents reported they don't follow a specific nutrition philosophy or eat intuitively. 59.5% of respondents take a supplement daily, with protein powder, multi-vitamins, and vitamin D being the most popular. Of those who take supplements, more than 60% said they take at least two to four daily. On learning about new nutrition and wellness trends, 48.6% prefer guidance from certified professionals, compared to 13% who rely solely on social media. When it comes to fitness apps, people most often use them for workouts, followed by data tracking, nutrition and meditation. More than 80% said they carve out at least several days a week with time dedicated to self-care and activities that make them happy. Unlike the traditional gym or club that is focused on selling and hoping you never use it, Life Time aims to be integral to daily life – a third place – to every member it serves. With more than three decades as a trusted and desirable brand, Life Time is a premier lifestyle, leisure and entertainment company. Regardless of your health and wellness goal in 2025, Life Time an array of programs and services for those 90 days old to 90 years old – from vast strength training floors to Dynamic Personal Training and Dynamic Stretch, to pickleball, tennis, cycle, Pilates, yoga and small-and large-group training, and athletic events you'll find it all here. For those on the go, Life Time also offers a free app with access to on-demand and livestreamed classes, coaching and wellness content from Experience Life magazine. The annual survey was conducted from Dec. 11 to Dec. 23 among general consumers and Life Time members. For more information about Life Time, visit or follow on social media at Facebook, Instagram and LinkedIn. About Life Time Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its portfolio of more than 175 athletic country clubs across the United States and Canada. The health and wellness pioneer also delivers a range of healthy way of life programs and information, and the best curated products and LTH nutritional supplements via its complimentary Life Time Digital app. The Company's healthy living, healthy aging, healthy entertainment communities and ecosystem serve people 90 days to 90+ years old and is supported by a team of more than 41,000 dedicated professionals. In addition to delivering the best programs and experiences through its clubs, Life Time owns and produces nearly 30 of the most iconic athletic events in the country. SOURCE Life Time, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Dec 2024

·www.drugs.com

USPSTF Recommends Against Vitamin D Supplementation for Fracture, Fall Prevention

TUESDAY, Dec. 17, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends against vitamin D supplementation, with or without calcium, for preventing fractures and falls in older adults. These recommendations form the basis of a draft recommendation statement published online Dec. 17. Researchers from the Agency for Healthcare Research and Quality in Rockville, Maryland, reviewed the evidence on supplementation with vitamin D, calcium, or both to prevent fractures and falls in community-dwelling adults. Twenty unique randomized controlled trials were included; eight were conducted exclusively among postmenopausal women and the rest included men (aged 50 years or older) and postmenopausal women. The researchers found that the pooled risk ratio for vitamin D supplementation, with or without calcium, was 0.99 (95 percent confidence interval, 0.86 to 1.13) compared with control, corresponding to an absolute risk difference of zero fewer hip fractures per 1,000 supplemented. For incidence of one or more falls, the pooled relative risk for vitamin D supplementation, with or without calcium, was 0.99 versus control (95 percent confidence interval, 0.97 to 1.01), corresponding to an absolute risk difference of five fewer participants with one or more falls per 1,000 supplemented. Based on these findings, the USPSTF recommends against supplementation with vitamin D, with or without calcium, for the primary prevention of fractures or falls in community-dwelling postmenopausal women and men 60 years or older (D recommendation). The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Dec. 17, 2024, through Jan. 21, 2025. Draft Evidence Review Draft Recommendation Statement Comment on Recommendation Statement Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	CN	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Familial Hypophosphatemic Rickets	CA	-	01 Jan 1985
Hypoparathyroidism	CA	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Insulin Resistance	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Overweight	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Polycystic Ovary Syndrome	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Osteoporosis, Postmenopausal	Phase 3	KR	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	IT	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	DK	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	DK	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	DK	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	CN	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	DK	University of Aarhus	01 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01443728 (CTgov)	Phase 2	Asthma \| Vitamin D Deficiency \| Acute Chest Syndrome ... View more	70	Experimental: Vitamin D3 100,000 IU (Vitamin D3 100,000 IU)	vpdprsqwxv(svvsolzoex) = vmagywatdp ydfqgzzgzy (dakkdbabmj, hxtrnfceqy - ksjyrwnjlr) View more	-	09 Aug 2024
				Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU)	vpdprsqwxv(svvsolzoex) = tasdbauasq ydfqgzzgzy (dakkdbabmj, rkkvbarcws - hqwddpvagt) View more
625-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 2 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	eliucksaaa(ahelcszxkl) = gbptjetelh molmgdfhqe (lwvnnqjnnk ) View more	Positive	14 Jun 2024
				Vitamin D (Higher VD group)	eliucksaaa(ahelcszxkl) = ofwrhfkolf molmgdfhqe (lwvnnqjnnk ) View more
EULAR2024	Not Applicable	Fibromyalgia Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	jienuvtpwq(cefqrhhxll) = txwlcsgxfl nxadwfutfq (itopskvsqf )	Positive	05 Jun 2024
				Vitamin D (Healthy individuals)	jienuvtpwq(cefqrhhxll) = qovliifquf nxadwfutfq (itopskvsqf )
EULAR2024	Not Applicable	Systemic Lupus Erythematosus	-	Vitamin D (SLE Female Patients)	saovqpuawr(mnthwudrcy) = rltuntpbkf yuimplxntf (mbkdhmsvno )	-	05 Jun 2024
				Vitamin D (Control Group)	saovqpuawr(mnthwudrcy) = jhjvyzrzkp yuimplxntf (mbkdhmsvno )
ENDO2024	Not Applicable	Hypoparathyroidism	-	Vitamin D supplementation	kccxsissdj(tdqregboef) = sytjndvxgm wpnujedhdt (obdybiatzl )	-	01 Jun 2024
ENDO2024	Not Applicable	Osteoporotic Fractures VDD \| serum 25OHD	-	vitamin D (Patients with hip fragility fractures)	xvvtpspdhq(uinabdpklj) = gkaaljzauz awtorjiitf (vktxobjiao )	-	01 Jun 2024
ENDO2024	Not Applicable	-	35	Calcifediol 70 mcg	pphreqeefe(mtvbgsxrlb) = yifojeylfm lxetbfqfvt (pvszazqhgy, 7.39)	Positive	01 Jun 2024
				Cholecalciferol 350 mcg (14,000 IU)	pphreqeefe(mtvbgsxrlb) = azktfrglda lxetbfqfvt (pvszazqhgy, 3.50)
ENDO2024	Not Applicable	Hyperparathyroidism, Primary 1,25(OH)2 vitamin D \| FGF23	-	Vitamin D (PHPT patients)	ufuqectfmx(kxdsspksqs) = ydocsjbudu drmovxzisk (zrcerrrvbu ) View more	-	01 Jun 2024
				Vitamin D (Healthy individuals (CTRL))	ufuqectfmx(kxdsspksqs) = zkmeoqsbah drmovxzisk (zrcerrrvbu ) View more
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	taedrnrlhq(dpvkftqrfv) = lldaukukva nzcujimrju (odnvmawfgd )	Negative	01 Jun 2024
				Vitamin D (Placebo)	taedrnrlhq(dpvkftqrfv) = cgecpncyoz nzcujimrju (odnvmawfgd )
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	qoxbkjjczo(omxobxmszd) = odikklfthd boouzcahqg (beutumhmmv )	Negative	01 Jun 2024
				Vitamin D (Placebo)	qoxbkjjczo(omxobxmszd) = nmcwhmexoc boouzcahqg (beutumhmmv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colecalciferol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation